In an initial screen, riluzole, one of the two therapies offered to ALS patients, reduced N-terminal TDP-43 interactions by 82%, whilst chelerythrine and auranofin reduced interactions by 64% and 63%, respectively. Here, TARDBP is linked to amyotrophic lateral sclerosis.